Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 2,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions: Enpatoran; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Billerica, Massachusetts

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Conditions: Hair Thinning
Interventions: Active Comparator- Xtressé™ Supplement and Serum, Placebo Comparator- Placebo Supplement and Serum; Dietary Supplement
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Aventura, Florida

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Octreotide LAR Depot, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more

Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Interventions: EYC-0305; Biological
Lead sponsor: Eyconis INC.; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Beverly Hills, California • Modesto, California • Wake Forest, North Carolina + 4 more

Conditions: Kidney Transplantation
Interventions: AEB071, mycophenolic plus tacrolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: San Francisco, California • Madison, Wisconsin

Conditions: Schizophrenia
Interventions: Aripiprazole once-monthly; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Herpes Zoster
Interventions: HZ/su vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 3,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more

Conditions: Early Stage HER2+ Breast Cancer
Interventions: Neratinib, Loperamide, Colestipol, Budesonide; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Corona, California • Fullerton, California + 36 more

Conditions: Alopecia Areata
Interventions: Tofacitinib; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Ravulizumab, Eculizumab; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • Baltimore, Maryland + 2 more

Conditions: Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome
Interventions: Guadecitabine; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Buffalo, New York • Durham, North Carolina • Columbus, Ohio + 2 more

Conditions: Crohn's Disease
Interventions: GSK1605786A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 49 more

Conditions: Sjögren's Syndrome
Interventions: Dazodalibep; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Avondale, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 27 more

Conditions: Primary Fibromyalgia
Interventions: Milnacipran; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 24 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more

Conditions: Menorrhagia
Interventions: Tranexamic acid; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 92
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more

Conditions: Psoriatic Arthritis
Interventions: Alefacept, Methotrexate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Birmingham, Alabama • Wheaton, Maryland • Lake Success, New York + 2 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Pemziviptadil (PB1046) Injection; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 10 more

Conditions: Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions: AIN457 150 mg, AIN457 300 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 28
States / cities: Fresno, California • Pasadena, California • San Francisco, California + 24 more

Conditions: Transfusional Iron Overload, Beta-thalassemia
Interventions: SPD602 (FBS0701, SSP-004184); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Oakland, California • Boston, Massachusetts

Conditions: Uremic Pruritus
Interventions: CR845 0.5 mcg/kg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 57
States / cities: Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more

Conditions: ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum, Generalized Arterial Calcification of Infancy
Interventions: INZ-701; Drug
Lead sponsor: Inozyme Pharma; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Eatontown, New Jersey

Search by objective public record fields.

A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients

Aripiprazole Once-monthly in Patients With Schizophrenia

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Guadecitabine Extension Study

Open-Label Extension Study of GSK1605786A

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE